SCHEMBL3477191

SCHEMBL3477191

Nc1[nH]c2ccc(Cl)cc2c1S(=O)(=O)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR2 O15552 5/20 0.60
CA1 P00915 3/20 0.53
CA2 P00918 3/20 0.53
PTGS2 P35354 4/20 0.47
ROCK2 O75116 1/20 0.47
MAP4K4 O95819 1/20 0.47
LCK P06239 1/20 0.47
CSF1R P07333 1/20 0.47
PIM1 P11309 1/20 0.47
RPS6KB1 P23443 1/20 0.47
CDK2 P24941 1/20 0.47
MAPK1 P28482 1/20 0.47
EPHA2 P29317 1/20 0.47
FLT3 P36888 1/20 0.47
FRK P42685 1/20 0.47
CLK2 P49760 1/20 0.47
GSK3A P49840 1/20 0.47
GSK3B P49841 1/20 0.47
LIMK1 P53667 1/20 0.47
STK3 Q13188 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3478192 0.85 TUBB4A (0.48) FFAR2CA1CA2PTGS2ROCK2
SCHEMBL3476563 0.82 TUBB4A (0.47) FFAR2CA1CA2PTGS2ROCK2
L-737126 SCHEMBL2344264 0.81 MAP2 (0.61) CA1CA2PTGS2TUBB4ATUBB
L-737126 SCHEMBL31654105 0.81 MAP2 (0.61) CA1CA2PTGS2TUBB4ATUBB
SCHEMBL8687789 0.81 MAP2 (0.59) PTGS2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL2879576 0.80 TUBB4A (0.53) FFAR2CA1CA2PTGS2CDK2
SCHEMBL2879949 0.80 TUBB4A (0.44) FFAR2CA1CA2PTGS2ROCK2
SCHEMBL3476881 0.79 TUBB4A (0.46) FFAR2PTGS2TUBB4ATUBBTUBA3C
SCHEMBL2881831 0.78 TUBB4A (0.51) FFAR2CA1CA2PTGS2CDK2
SCHEMBL3835183 0.78 TUBB4A (0.48) FFAR2CA1CA2PTGS2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010132869-A2 PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE GOVERNMENT OF THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2010-11-18 WO disclosed
US-20100179122-A1 Non-Nucleoside Reverse Transcriptase Inhibitors MERCK SHARP & DOHME CORP. 2010-07-15 US disclosed
EP-1898927-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Merck & Co., Inc. (US) 2008-03-19 EP disclosed
WO-2007002481-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179122-A1 Non-Nucleoside Reverse Transcriptase Inhibitors RNGTT, RTF1, POLR1E FFAR2 4500/4885CA1 4532/4885CA2 4294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.